Allergan India Private Limited

Allergan India Private Limited
Corporation

Allergan India Private Limited
Prestige Obelisk Level 6 And Level 7 Kasturba Road
Bangalore 560001
Karnataka
India

Contact Customer Care
Allergan
Contact Phone
Contact Email
IN-Allergan@Allergan.com

Read About Corporation

We're a global, integrated specialty pharmaceutical company.

Leading Growth Pharma

ALLERGAN INDIA PVT. LTD.

Allergan India Private Limited, a joint venture between Allergan and Piramal Healthcare Limited (Formerly known as Nicholas Piramal India Limited), commenced commercial operations in 1996. Allergan India is a specialty pharmaceutical company. It has emerged as the market leader in the fast growing ophthalmic category with the successful launches of a series of high technology medication and devices for diseases such as glaucoma, dry eye, infections and inflammations. 

Allergan India is today the partner of choice for majority of the Ophthalmologists in the country. Allergan India is poised to grow at a rapid pace. Allergan is the undisputed leader in the Eyecare pharma market with dominance in all major disease segments.

ALLERGAN HEALTHCARE INDIA PVT. LTD.

Allergan Healthcare India Private Limited, is a 100% subsidiary of Allergan. Our Facial Aesthetics & Neurosciences business, with Botox® and Juvederm® is making waves in the Indian market and poised for a giant leap forward.

In India, we have approximately 500+ talented employees.

100 Countries

Allergan is a $23 billion diversified global pharmaceutical company and a leader in a new industry model - Growth Pharma. The company is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team creating an unrivaled foundation for long-term growth.

Research and Development

Together, our Company is focused on developing new medicines that address unmet medical needs in critical therapeutic areas, as well as increasing global access to high-quality, affordable medicines.

Driving continued innovation and growth is the combined company’s strong commitment to R&D, with an investment of ~$1.7 billion in 2015, focused on strategic development of innovative and durable value-enhancing products within brands, generics, biologics and OTC portfolios.